Inactive Instrument

BioHemp International, Inc.

BKIT

US09076B1052

Biohemp International, Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019

July 15, 2019 at 05:04 pm EDT

BioHemp International, Inc. announced earnings results for the third quarter ended May 31, 2019. For the third quarter, the company announced net loss was USD 9,451 compared to USD 16,089 a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.49 a year ago. For the nine months, net loss was USD 27,706 compared to USD 24,065 a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.74 a year ago.

Latest news about BioHemp International, Inc.

Biohemp International, Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019	19-07-15	CI
Biohemp International, Inc. Enters Agreement with American Premium Water Corporation to White Label Cannabidiol Infused Water Utilizing HIPH’s Proprietary Hydro Nano Technology	19-07-11	CI
BioHemp International, Inc. Appoints Ryan Fishoff as Lead Advisor to the Company	19-06-24	CI
Blake Insomnia Therapeutics, Inc. has Changed its Name to BioHemp International, Inc	19-06-18	CI
Blake Insomnia Therapeutics, Inc. Announces Management Changes	19-05-17	CI
Blake Insomnia Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended February 28, 2019	19-04-23	CI
Blake Insomnia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2018	19-02-27	CI
Blake Insomnia Therapeutics, Inc. will Change its Ticker to BKIT from BKITD	18-11-26	CI
Blake Insomnia Therapeutics, Inc. Announces Management Changes	18-03-12	CI
Blake Insomnia Therapeutics, Inc. announced that it expects to receive $1 million in funding	17-09-05	CI
Blake Insomnia Therapeutics Inc. Announces Submitting Clinical Trial Application for Phase II Clinical Testing to Health Canada	17-08-25	CI
Blake Insomnia Therapeutics Appoints Morten Albrechtsen to its Board of Directors	17-06-16	CI
Blake Insomnia Therapeutics Inc. Announces Board Appointments	17-05-25	CI
Blake Insomnia Therapeutics, Inc. Appoints Eric Leire to its Board of Directors	17-05-09	CI
Blake Insomnia Therapeutics Inc. Announces Joint Venture with Sajo Consulting LLC	17-02-25	CI
Blake Insomnia Therapeutics, Inc. Enters Joint Development with Sajo Consulting LLC	17-02-07	CI
BioHemp International, Inc. Auditor Raises 'Going Concern' Doubt	15-12-14	CI
Book it Local, Inc. has Changed its Name to Blake Insomnia Therapeutics, Inc	15-09-01	CI
Blake Insomnia Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	14-12-18	CI
Book It Local, Inc. will Change its Ticker to BKIT from BKITE	13-12-20	CI
Blake Insomnia Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	13-12-17	CI
Book It Local Inc. announced that it expects to receive $0.10 million in funding.	12-08-13	CI

Chart BioHemp International, Inc.

Duration

Period

More charts

Company Profile

BioHemp International, Inc., formerly Blake Insomnia Therapeutics, Inc., is a development-stage pharmaceutical company. The Company operates as a provider of insomnia remedy. The Company is focused on developing its business plan for an insomnia medication known as Zleepax. Zleepax is a sleep aid with beta-blockers as an active agent. As of August 31, 2016, the Company had no revenues.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals